In this diverse cohort study of 1500 children, the trajectory of cardiovascular health scores began to decline at around age 10, associated with health behaviors rather than health factors.
Children and adolescents with multiple sclerosis (MS) have a range of symptoms, signs, and diagnoses within 5 years before diagnosis, according to a study publi ...
The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...
Nursing staff interventions regarding shock team activation significantly improved the time of diagnosis and acceptance of patients with cardiogenic shock. A cardiovascular specialty hospital in north ...
The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...
The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound is a dual ...
The researchers noted that there is still an urgent need for more research on the most appropriate diagnostic and treatment options for POI. They emphasized the impact of estrogen deficiency on ...